

Contents

- 52** H. Uemura, Y. Nakagawa, Y. Hirao, E. Okajima, K. Yoshikawa, E. Oosterwijk
Expression of MN Antigen in Urologic Cancer: Potential Tool as a Therapeutic Target
- 55** U. Jonas, K. Höfner, H. Madersbacher, T. H. Holmdahl, R. Freeman, C. Anderstrom, A. Mattiasson, P. Abrams and the Participants of the International Study Groups Tolterodine – A New Drug for the Treatment of Urge Incontinence. Clinical and Urodynamic Efficacy and Comparison with Oxybutynin
- 61** Ch. Gittermann, M. Heitz, T. Pottek, F. Schreiter
VESICA®-Percutaneous Bladder Neck Suspension: Why Doesn't it Work?
- 64** H. Onda, M. Yasuda, A. Serizawa, R. Y. Osamura, N. Kawamura
Analysis of Immunohistochemical Expression of PCNA (Proliferating Cellular Nuclear Antigen) and MIB-1 (Ki-67 Antigen) as a Prognostic Indicator for Renal Cell Carcinoma
- 68** H. Ishida, T. Hachiya, K. Okada
Tumor Reduction Effect of Neoadjuvant Androgen Ablation Therapy for Prostate Cancer; Pathological Evaluation and Clinical Prediction
- 70** G. H. Mickisch, R. Kranse
Patterns of Failure After Surgically Radical Resection for Organ-Confining Prostate Cancer
- 74** M. P. Wirth, U. Fiedler
Molecular markers in prostate cancer
- 78** G. Steiner, M. P. Schoenberg, L. Mao, D. Sidransky, S. C. Müller
Diagnosis of recurrent bladder cancer by microsatellite analysis of the urine sediment (MAUS)
- 83** R. von Knobloch, D. Schullerus, H. Riedmiller, T. Kälble
Allelic Imbalance at Chromosomes 5q, 8p and 17p as Progression Markers for Bladder Cancer?
- 87** D. Jocham, T. Gaertner
Photodynamic Diagnosis and Therapy in Urology
- 92** T. S. Pottek, M. Heitz, M. Hartmann, F. Schreiter
Malignant LEYDIG-Cell-Tumours: Age as a Risk-Factor